Furthermore, a recent study relying on CRISPR-based techniques to modify the TP53 status of human cancer cell lines or cancer-derived organoids recently led to the conclusion that mutant p53 removal had no impact on the properties of tumor cells in vitro and in vivo [13]. This evidence concerns the gene TP53 and neoplasm.